🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ray Dalio’s INDV Holdings & Trades

First Buy
Q1 2026
Duration Held
1 Quarters
Largest Add
Q1 2026
+37,141 Shares
Current Position
37,141 Shares
$1.13 M Value

Ray Dalio's INDV Position Overview

Ray Dalio (via Bridgewater Associates, Lp) currently holds 37,141 shares of Indivior Pharmaceuticals, Inc. (INDV) worth $1.13 M, representing 0.01% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Ray Dalio has initiated a new position in INDV, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Ray Dalio's Indivior Pharmaceuticals (INDV) Holding Value Over Time

Track share changes against reported price movement

Quarterly Indivior Pharmaceuticals (INDV) Trades by Ray Dalio

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +37,141 New Buy 37,141 $30.48

Ray Dalio's Indivior Pharmaceuticals Investment FAQs

Ray Dalio first purchased Indivior Pharmaceuticals, Inc. (INDV) in Q1 2026, acquiring 37,141 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ray Dalio has held Indivior Pharmaceuticals, Inc. (INDV) for 1 quarters since Q1 2026.

Ray Dalio's largest addition to Indivior Pharmaceuticals, Inc. (INDV) was in Q1 2026, adding 37,141 shares worth $1.13 M.

According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 37,141 shares of Indivior Pharmaceuticals, Inc. (INDV), valued at approximately $1.13 M.

As of the Q1 2026 filing, Indivior Pharmaceuticals, Inc. (INDV) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.

Ray Dalio's peak holding in Indivior Pharmaceuticals, Inc. (INDV) was 37,141 shares, as reported at the end of Q1 2026.